Study PI3K as a Key Target in Glioblastoma
Time: 2:15 pm
day: Day Two
Details:
- Explore opportunities and challenges associated with modulating PI3K
as a therapeutic strategy in glioblastoma - Examine The significance of biomarkers in patient selection
- Review emerging clinical data from paxalisib, a brain penetrant PI3K /
mTOR inhibitor
Speakers:
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. He has been responsible for several large-scale international clinical programs, and for…Read more